NIAID Banner Logo Image

Other Viruses Citation List: October 12 - October 25, 2012

Hepatitis C Virus

1. 841 BC556, a Potent, Pan-genotypic, High Barrier to Resistance, Second Generation Cyclophilin Inhibitor for Treatment of Chronic HCV Infection. Moss, S.J., J.A. Garcia-Rivera, P. Leyssen, N. Coates, T. Foster, S. Kendrew, M. Nur-E-Alam, A.E. Stanley, D. Suthar, T. Warneck, J. Neyts, P. Gallay, B. Wilkinson, and M.A. Gregory. Journal of Hepatology, 2012. 56: p. S328.

[PubMed] OV_1012-102512.

2. The Relative Efficacy of Boceprevir and Telaprevir in the Treatment of HCV Genotype 1. Schmitz, S., A. O'Leary, C. Walsh, C. Bergin, and S. Norris. Clinical Infectious Diseases, 2012. [Epub ahead of print]; PMID[23074309].

[PubMed] OV_1012-102512.

3. A New Class of Pyrimidine Nucleosides: Inhibitors of Hepatitis B and C Viruses. Shakya, N., S. Vedi, C. Liang, B. Agrawal, D. Lorne Tyrrell, and R. Kumar. Bioorganic & Medicinal Chemistry Letters, 2012. 22(20): p. 6475-6480; PMID[22985854].

[PubMed] OV_1012-102512.

4. In Vitro Activity of Daclatasvir on Hepatitis C Virus Genotype 3 NS5A. Wang, C., L. Valera, L. Jia, M.J. Kirk, M. Gao, and R.A. Fridell. Antimicrobial Agents and Chemotherapy, 2012. [Epub ahead of print]; PMID[23089758].

[PubMed] OV_1012-102512.

Citations from the ISI Web of Knowledge Listings for O.V.

5. Melatonin Attenuates Inflammation and Promotes Regeneration in Rabbits with Fulminant Hepatitis of Viral Origin. Laliena, A., B. San Miguel, I. Crespo, M. Alvarez, J. Gonzalez-Gallego, and M.J. Tunon. Journal of Pineal Research, 2012. 53(3): p. 270-278; ISI[000308585500006].

[WOS]. OV_1012-102512.

6. NS5A Inhibitors to Treat Hepatitis C Virus Infection. Welzel, T.M. and S. Zeuzem. Lancet Infectious Diseases, 2012. 12(9): p. 648-649; ISI[000307916300002].

[WOS]. OV_1012-102512.

If using ChemDB information for publication or abstract presentation, please cite the website in addition to the original information source.    Database last updated: May 2022